About Metabolon
Metabolon is a company based in Morrisville (United States) founded in 2000. Metabolon has raised $165.87 million across 19 funding rounds from investors including Sumitomo Corporation, ARE and East West Bank. Metabolon has completed 2 acquisitions, including Lipomics and Metabolomic Discoveries. Metabolon offers products and services including Bioinformatics Platform, Untargeted Metabolomics, Targeted Metabolomics, and Lipidomics. Metabolon operates in a competitive market with competitors including Maze Therapeutics, Alector, Seer, Tango Therapeutics and NeoPhore, among others.
- Headquarter Morrisville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$165.87 M (USD)
in 19 rounds
-
Latest Funding Round
$7.5 M (USD), Series H
Dec 31, 2024
-
Investors
Sumitomo Corporation
& 14 more
-
Employee Count
Not available
-
Investments & Acquisitions
Lipomics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Metabolon
Metabolon offers a comprehensive portfolio of products and services, including Bioinformatics Platform, Untargeted Metabolomics, Targeted Metabolomics, and Lipidomics.
Tool for visualizing and analyzing metabolomics data sets
Analysis of wide-ranging metabolites for research
Quantification of specific metabolites for studies
Identification of lipid species in biological samples
People of Metabolon
Unlock access to complete
Sales and Marketing
16 people
Leadership Team
13 people
Data Analysis and Operations Team
6 people
Product Management Team
6 people
Senior Team
5 people
Principal Team
4 people
Finance and Accounting
3 people
Operations Team
2 people
Unlock access to complete
Funding Insights of Metabolon
Metabolon has successfully raised a total of $165.87M across 19 strategic funding rounds. The most recent funding activity was a Series H round of $7.5 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Metabolon
Metabolon has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Sumitomo Corporation, ARE and East West Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified debt funding is provided for growth capital opportunities.
|
Locked | Locked | Locked | |
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Locked | Locked | Locked | |
|
Growth equity investments are made in lower middle market companies.
|
Locked | Locked | Locked |
Investor details for Metabolon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Metabolon
Metabolon has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Lipomics and Metabolomic Discoveries.
Investment portfolio details for Metabolon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Metabolomic data analysis software and services are provided for research.
|
Locked | Locked | 2009 | Locked | |
|
Diagnostics for metabolic, cardiovascular, and inflammatory conditions are developed.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Metabolon
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Metabolon
Detailed financials for Metabolon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Metabolon Comparisons
Peer comparison for Metabolon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Metabolon
Metabolon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Maze Therapeutics, Alector, Seer, Tango Therapeutics and NeoPhore, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Novel cancer drugs are developed using synthetic lethality screening.
|
|
| Locked | Locked | Locked |
NeoPhore is focused on cancer neoantigen evolution therapies.
|
Detailed competitors of Metabolon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Metabolon
Complete news archive for Metabolon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Metabolon
Metabolon was founded in 2000 and raised its 1st funding round 3 years after it was founded.
Metabolon is headquartered in Morrisville, United States.
Metabolon is a funded company, having raised a total of $165.87M across 19 funding rounds to date.
Metabolon was founded in 2000 and is headquartered in Morrisville, United States. Operations focus on the biotechnology sector, where a biochemical profiling platform is utilized to analyze and identify biochemicals for research in pharmaceuticals, biotech, agriculture, cosmetics, and consumer products. Services include Quantose IR for prediabetes assessment and Meta IMD for detecting inborn errors of metabolism. Development of metabolomics-based tests for early detection of obesity-related metabolic diseases is ongoing.
Metabolon's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.
Metabolon offers Bioinformatics Platform, Untargeted Metabolomics, Targeted Metabolomics, and Lipidomics.
Metabolon has made 2 acquisitions, including Lipomics, and Metabolomic Discoveries.
Metabolon has 15 investors. Key investors include Sumitomo Corporation, ARE, East West Bank, HHS, and Fletcher Spaght.